CPS
  • Home

Sign in or register to track your progress, save, and view your completed history.

Breast Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head & Neck Cancer, Urothelial Carcinoma

Assessing PD-L1 Combined Positive Score (CPS) in Various Tumor Types with Distinct Morphological Characteristics

    clockimg 54m
  • Webinar
  • Intermediate
 saveimgSave unsaveimgUnsave

The Precision Pathology Insights webinar series brings you valuable perspectives from leading pathologists around the world. This webinar is presented by Dr. Philippe Tanière, histopathologist at University Hospitals Birmingham. The webinar is moderated by Greg Harlow, PhD, a Senior Medical Affairs Consultant at Agilent. Recorded on 7 October 2021.​

 

Dr. Tanière shares expert insight into:​

  • Specific indications and their unique PD-L1 staining characteristics​
  • Morphological features that can impact combined Positive Score (CPS) evaluation​
  • Implications for clinical utility and patient outcomes​
  • Real-world scoring and case example walkthroughs​

Philippe Tanière, MD​

Consultant Histopathologist, QEHB​

Greg Harlow, PhD

Senior Medical Affairs Consultant​, Agilent Technologies

Related Training

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details. D0113741_1.00​